Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Q2 FY2027 Earnings Presentation
84 slides from Jubilant Pharmova's earnings presentation, November 2026
Slide 1: Earnings Presentation Q2'FY27
Earnings Presentation Q2’FY27
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Jubilant Bhartia Group has created value across multiple sectors
Jubilant Bhartia Group has created value across multiple sectors Strong presence in diverse sectors • Pharmaceuticals • Contract Research & Development Services • Life Science Ingredients • Therapeutics • Performance Polymers • Auto Dealerships • Food Service (QSR) • Oil and Gas services • Beverages
Slide 4: Jubilant Pharmova, a diversified pharmaceutical company
Jubilant Pharmova, a diversified pharmaceutical company Radiopharma Allergy Immunotherapy CDMO Sterile Injectables Leading manufacturer 2nd largest player Leading contract manufacturer of Radiopharmaceuticals in the US Allergenic extract market in North America in North America Sole supplier of Veno
Slide 5: Focus on specialty products & services and Dollar revenues
Focus on specialty products & services and Dollar revenues Business wise Revenue Split Currency wise Revenue Split H1’FY27 H1’FY27 Generics, Rest, 10% 5% CRDMO, 14% Radiopharma, 44% CDMO - SI, 22% USD, 95% Allergy Immunotherapy, 10% Specialty Products (Radiopharma, Allergy Immunotherapy) – 54% and S
Slide 6: Minimal risk from US Tariffs
Minimal risk from US Tariffs Geography wise Revenue Split Origin of Goods & Services sold in the US H1’FY27 H1’FY27 Goods & Services from Rest of India, Goods & 8%* World, 21% Services from Canada, 16%* USA, 79% Goods & Services from US , 76% US market constitutes Goods from Canada (Radiopharmaceuti
Slide 7: State-of-the-art manufacturing and research facilities enable our growth
State-of-the-art manufacturing and research facilities enable our growth Kirkland, Montreal, Canada Spokane, Washington, US CDMO – SteriIe Injectables Radiopharmaceuticals CDMO – SteriIe Injectables Allergy Immunotherapy NORTH AMERICA 6 Manufacturing facilities Roorkee, Uttrakhand, India - Generics
Slide 8: Vision 2030: We aspire to double our revenues by FY30
Vision 2030: We aspire to double our revenues by FY30 and we are on the right track From To Actual FY24 FY30 TTM Q2’FY27 2x Revenue Rs. 6,703 Cr. Rs. 13,500 Cr. Rs. 9,012 Cr. 25% EBITDA Margin ~ 15 % 23% to 25% 13% Rs. 2,672 Cr. Zero Net Debt Rs. 2,457 Cr. Zero End of Q2’FY27 High Teens RoCE High Si
Slide 9: These are our growth drivers to achieve Vision 2030
These are our growth drivers to achieve Vision 2030 Business Growth Drivers Progress in Q2’FY27 Leadership in Ruby-Fill® Ruby-Fill® growth at 37% Radiopharma Launch New PET, SPECT and Therapeutic products (MIBG) Progressing in new products Invest in 6 high margin PET Manufacturing facilities in US N
Slide 10: Radiopharma
Radiopharma
Slide 11: Radiopharmaceuticals
Radiopharmaceuticals SPECT SPECT PET Radiopharmaceutical Radiopharmaceutical Imaging Imaging Imaging Therapeutics Therapeutics Low Energy High Energy Systemically or Locally gamma rays positrons Delivered detected by SPECT cameras detected by a PET scanner radiation using pharmaceuticals Isotopes -
Slide 12: US Radiopharmaceutical market is growing at rapid pace
US Radiopharmaceutical market is growing at rapid pace US Radiopharmaceutical Market Growth Drivers & Trends USD Bn. Launch of advanced • PSMA Therapeutic, Pluvicto for Prostrate Cancer ~USD 2.0 Bn. 3.1x Therapies 2.8x 1.2x • PSMA Diagnostics for Prostrate Cancer ~ USD 1.8 Bn. New 9.7 products in •
Slide 13: Jubilant Radiopharma – Integrated player with Radiopharma Development, GMP Manufacturing and distribution network
Jubilant Radiopharma – Integrated player with Radiopharma Development, GMP Manufacturing and distribution network Radiopharmaceutical Plant, Montreal, Canada 2nd largest Radiopharmacy Network, US WD Portland MT ND ME OR ID MN VT Saginaw NH SD WI Minneapolis NY Bost WY MI DetroitWilk Phil RI on San F
Slide 14: Integrated platform across the value chain
Solid foundation in SPECT Imaging, Poised to develop PET imaging agents & the supply chain for PET and Therapeutics SPECT PET Therapeutics • Integrated platform across the value chain • Strong and growing product Rapidly growing Cardiac • 80% share in I-131 portfolio Imaging franchise and a robust •
Slide 15: Consolidated Market with high Entry Barriers
Consolidated Market with high Entry Barriers Stringent manufacturing & regulatory environment Adherence with extensive license framework. Stringent manufacturing set up required to handle isotopes Managing time sensitive Forward integration logistics with radiopharmacies Radioactive isotope decays F
Slide 16: We are a leading Radiopharmaceuticals manufacturer in North America
We are a leading Radiopharmaceuticals manufacturer in North America Organ Key Indication Product PET Dx Cardiac Coronary Artery disease Ruby - Fill® Breast Lymph nodes detection Sulfur Colloid Cardiac blood pool imaging Tc99m-Gluceptate • Diversified across diagnostics & therapeutics Cardiac Coronar
Slide 17: Market leadership in select products
Market leadership in select products Draximage ® MAA Draximage ® DTPA Ruby-Fill ® HICON® Sodium Iodine I 131 Solution USP It is used for Cardiac PET scan, MAA is used in the perfusion DTPA is used to assess HICON® is a radioactive to evaluate regional myocardial phase of a ventilation/perfusion pulm
Slide 18: Radiopharmaceuticals Financials: Q2'FY27 & H1'FY27
Radiopharmaceuticals Financials : Q2’FY27 & H1’FY27 Particulars ( Rs. Cr.) Q2’FY26 Q1’FY27 Q2’FY27 Y-o-Y H1'FY26 H1'FY27 Y-o-Y • Revenue grew strongly on back of growth in Ruby-Fill ® Revenue 291 322 342 18% 561 664 18% • EBITDA margins decreased YoY due to unavailability of high margins SPECT produ
Slide 19: Radiopharmaceuticals Vision 2030: To more than double the revenues
Radiopharmaceuticals Vision 2030: To more than double the revenues EBITDA margins impacted by unavailability of high margin SPECT Revenue: Products due to lower production at CMO Montreal. Margins to improve More than 2x of FY24 as supply increases EBITDA Margin: EBITDA margins to further improve po
Slide 20: To become leader in cardiac PET Imaging through Ruby-Fill
To become leader in cardiac PET Imaging through Ruby-Fill® Ruby-Fill ® Rubidium 82 generator Competitive advantage Growth drivers: and Elusion System • Longer life per generator (7 weeks vs 6 weeks for peer) • Ruby-Fill® • Better image quality and consistency • Constant Activity • New PET & SPECT pr
Slide 21: Launch new PET and SPECT imaging products with a TAM of USD 535 Mn
Launch new PET and SPECT imaging products with a TAM of USD 535 Mn Developing new products in SPECT Imaging to maintain leadership & in PET Imaging for growth Growth drivers: • Ruby-Fill® Incremental Potential Peak Milestone No. of CMO Exhibit End of Timeline TAM Annual Sales Filing Launch • New PET
Slide 22: Launch MIBG by CY27
Launch MIBG by CY27 HICON® Sodium Iodide I 131 - Commercialised MIBG - Undergoing Clinical trials Growth drivers: • Ruby-Fill® • Blinded independent • New PET & SPECT review progressing products • NDA filing post FDA • MIBG meeting by Q4’FY27 • Potential peak sales USD 70 - 100 Mn. • Iodine I 131, H
Slide 23: Radiopharmacy
Ze, 3 | 94 \ 95 \ 9% \ 9 \p \ Pu \ Am \ Cn as Si \eptunium, \ pron \ aoe ew cuttum |
Slide 24: Radiopharmacies are critical in generating value
Radiopharmacies are critical in generating value Growth Drivers & Trends SPECT Radiopharmacy PET Manufacturing Facility • Consolidated market in the US. Large M&A transactions in Radiopharmacies • Increasing demand for novel PET products driving PET radiopharmacies growth • Stringent USP 825 regulat
Slide 25: Consolidated market with high Entry Barriers
Consolidated market with high Entry Barriers Consolidated Market Barriers to Entry 1 Stringent Regulations # of # of radio SPECT PET hospitals Each treatment site is required to obtain a license pharmacies Manufacturing in the US Pharmacies Facility served in the US from Nuclear Regulatory Commissio
Slide 26: The 2nd largest radiopharmacy network in the US
The 2nd largest radiopharmacy network in the US 45 Current SPECT Current Cyclotron 6 New PET SITES Radiopharmacies USP<825> JDR network is USP 825 with ~ 20% WD compliant Portland volume market MT ND ME share OR MN VT ID Saginaw NH SD Minneapolis WI NY Boston Business moat 1,800 WY MI Detroit Wilkes
Slide 27: Radiopharmacy Financials: Q2'FY27 & H1'FY27
Radiopharmacy Financials : Q2’FY27 & H1’FY27 Particulars ( Rs. Cr.) Q2’FY26 Q1’FY27 Q2’FY27 Y-o-Y H1'FY26 H1'FY27 Y-o-Y • Revenue grew YoY on the back of increase in volume from certain PET products. Higher Revenue 607 700 667 10% 1,204 1,367 14% competitive intensity in SPECT continues EBITDA 8 12
Slide 28: Radiopharmacy Vision 2030: Double the revenues, expand margins
Radiopharmacy Vision 2030: Double the revenues, expand margins by adding 6 PET Manufacturing Facilities Revenue: Growth and Margins to improve as New (6) PET 2x of FY24 manufacturing facilities become operational EBITDA Margin: ~ 7% to 8% Revenue: Rs. 2,675 Cr. Revenue: Rs. 2,512 Cr. EBITDA Margin:
Slide 29: Expanding PET Manufacturing Facilities from current 3 sites to 9 sites
Expanding PET Manufacturing Facilities from current 3 sites to 9 sites Growth driver: • PET expansion • Strengthened network to enable long term contracts with PET radiopharmaceutical manufacturers • Fully operational by FY28. Funding through internal accruals and long-term credit • Investment of US
Slide 30: Allergy Immunotherapy
Allergy Immunotherapy
Slide 31: Allergy immunotherapy is the sole way to fundamentally reduce allergen hypersensitivity
Allergy immunotherapy is the sole way to fundamentally reduce allergen hypersensitivity • 20% + global population have allergies e.g. Asthma and Allergenic Rhinits • Allergy Immunotherapy requires repeated shots of allergic antigens to develop immunity Allergies Testing Treatment 31
Slide 32: Global Allergy Immunotherapy market is expected to grow by ~7%
Global Allergy Immunotherapy market is expected to grow by ~ 7% Global Allergy Immunotherapy Market Growth Drivers and Trends USD Bn. • Concentrated US market with 3 players 3.0 • Complex supply chain from sourcing to processing 2.2 2.7 • Grandfathered approvals, new product needs BLA 2.0 0.2 0.3 •
Slide 33: 2nd largest player in the US Sub-Cutaneous Allergy Immunotherapy market
2nd largest player in the US Sub-Cutaneous Allergy Immunotherapy market • 100-year-old ‘HollisterStier’ brand • Onshore US FDA approved manufacturing • Sole Supplier of Venom extracts in the US • Dedicated sales force in the US • 200+ allergenic & 6 venom extracts • 2,000+ Allergists / ENTs as custo
Slide 34: Allergy Immunotherapy Financials: Q2'FY27 & H1'FY27
Allergy Immunotherapy Financials : Q2’FY27 & H1’FY27 Particulars ( Rs. Cr.) Q2’FY26 Q1’FY27 Q2’FY27 Y-o-Y H1'FY26 H1'FY27 Y-o-Y • Revenue grew on the back of growth across US & Outside US markets Revenue 194 214 230 18% 375 444 18% • EBITDA margin lower YoY due to lower EBITDA 76 66 69 (10%) 139 134
Slide 35: Allergy Immunotherapy Vision 2030
Allergy Immunotherapy Vision 2030: Solidify position as a scientific leader Revenue: Growth & Margins on track ~1.5x of FY24 EBITDA Margin: 35% to 40% Revenue: Rs. 854 Cr. Revenue: Rs. 785 Cr. EBITDA Margin: 32% Revenue: Rs. 701 Cr. EBITDA Margin: 35% Revenue: Rs. 679 Cr. EBITDA Margin: 35% EBITDA M
Slide 36: Allergy Immunotherapy Growth Drivers
Allergy Immunotherapy Growth Drivers Strengthen competitive Grow outside US Increase investment position in US business in R&D • Retain and grow Venom • Develop new products & customers & patient base • Increase outside US technologies Venom sales through strategic partnerships in • Increase US reve
Slide 37: CDMO - Sterile Injectables
~ a Me ore |) >} CDMO - Sterile | Injectables
Slide 38: CDMO - Sterile Injectables is seeing demand supply gap widening
CDMO - Sterile Injectables is seeing demand supply gap widening Global CDMO-SI Market Size Growth Drivers & Trends USD Bn 20 • Innovator Pharma companies, for their US 17 16 requirement, are planning to shift the 14 13 manufacturing from Europe to US, as a risk mitigation measure due to impending Ta
Slide 39: Market with high Entry Barriers
Market with high Entry Barriers • Majority of commercial contracts are typically long duration (typically 3 years or more with auto renewal) • Greenfield expansion is considerably difficult due to high up-front capex required with ongoing opex to support initial product commercialization • Innovator
Slide 40: We are a leading North American CDMO player with unique capabilities
We are a leading North American CDMO player with unique capabilities and strong customer relationships • 5 of the top 20 pharma companies as customers • 25+ customers across the world with multiple products having patent protection and limited competition • 5+ years average relationship time with To
Slide 41: CDMO Sterile Injectables Financials: Q2'FY27 & H1'FY27
CDMO Sterile Injectables Financials : Q2’FY27& H1’FY27 TOTAL • Revenue grew strongly on YoY due to Q2’FY26 Q1’FY27 Q2’FY27 Y-o-Y H1'FY26 H1'FY27 Y-o-Y Particulars ( Rs. Cr.) incremental revenues from Line 3 at Spokane. Revenue 393 496 522 33% 763 1,019 33% • EBITDA margin lower YoY due to higher ope
Slide 42: CDMO - Sterile Injectables Vision 2030: Double revenues by doubling capacity
CDMO - Sterile Injectables Vision 2030 : Double revenues by doubling of capacity at Spokane Revenue expected to overshoot Revenue : Vision target More than 2x of FY24 EBITDA margins to improve with reduction of losses at CMO Montreal EBITDA Margin : More than 25% Revenue : Rs. 2,010 Cr. EBITDA Margi
Slide 43: Line 3 Technology transfer revenues continue to grow
Line 3 Technology transfer revenues continue to grow, Commercial Batch Production from FY28 Growth driver: • Doubling Capacity at Spokane Timeline FY’27 FY’28 FY’29 LINE 3 Technology Commercial Batch Moving to Peak transfer revenues Production utilization • Line 3 revenues scale up on the back of 13
Slide 44: Line 4 installation on track
Line 4 installation on track Technology transfers expected to start in FY27 Growth driver: • Doubling Capacity at Spokane Timeline FY’26 FY’27 FY’28 LINE 4 Installation Media Fill Commercial Production • Line 4 installation and media fills complete • Building a strong order book pipeline • Expect te
Slide 45: CMO Montreal Update
CMO Montreal Update Growth driver: • New Isolator Line at Montreal Existing Line • Production started for SPECT Radiopharmaceutical products. • Remediation work is in progress, Engaged with FDA • Continue lean operations in FY27 & FY28, till Line 5 becomes operational in FY29 New Isolator Fill & Fin
Slide 46: With Line 3 & 4, We are becoming a specialized CDMO
With Line 3 &4, We are becoming a specialized CDMO delivering complex biologics formulations for Innovators Traditional CDMO Line 3 & 4 • Product Mix ~ 80% small molecules & 20% Biologics • Product Mix projected at 20% small molecules & 80% with low formulation complexity Biologics with complex form
Slide 47: CRDMO: Drug Discovery Services, CDMO API
CRDMO: Drug Discovery Services, CDMO API
Slide 48: CRDMO: India uniquely positioned to benefit from Friendshoring
CRDMO: Drug Discovery, CDMO - API India uniquely positioned to benefit from Friendshoring Drug Discovery Services Market Size USD Bn. Growth Drivers & Trends 10 8 Drug Discovery Market • Biosecure Act advantage • Rise in specialized technologies such as ADCs and oligonucleotides 2023 2028 CDMO API M
Slide 49: We are a leading CRDMO for science with superior customer relationships
We are a leading CRDMO for science with superior customer relationships • ~ One third revenue contribution from Large Pharma accounts • Indian Leader for “Integrated Drug Discovery”, with a track record of 100+ programs and Big pharma strategic partnership • Strengthen European penetration, with mul
Slide 50: Integrated Discovery & Development Infrastructure
…with Integrated Discovery & Development Infrastructure Drug Discovery CDMO and API Integrated Chemistry Innovation Center of Excellence for Advanced Cetner for GMP CDMO & API Drug Discovery Center Research Center Biologics & ADCs PR&D and Scale-Up Manufacturing Facility (Bengaluru, India) (Delhi NC
Slide 51: Drug Discovery Financials: Q2'FY27 & H1'FY27
Drug Discovery Financials : Q2’FY27 & H1’FY27 Particulars ( Rs. Cr.) Q2’FY26 Q1’FY27 Q2’FY27 Y-o-Y H1'FY26 H1'FY27 Y-o-Y • Revenue increased YoY on the back of increase in revenue from biotech customers Revenue 162 174 180 11% 323 354 10% • EBITDA margins marginally decreased YoY due to change in pr
Slide 52: Drug Discovery Vision 2030: Triple revenues & maintain profitability
Drug Discovery Vision 2030 : Triple revenues & maintain profitability Revenue: Revenue growth and ~ 3x of FY24 Margins on track EBITDA Margin: More than 25% Revenue: Rs. 684 Cr. EBITDA Margin: 24% Revenue: Rs. 654 Cr. EBITDA Margin: 23% Revenue: Rs. 570 Cr. EBITDA Margin: 24% Revenue: Rs. 449 Cr. EB
Slide 53: Drug Discovery Services: Leverage Large Pharma potential
Drug Discovery Services: Leverage Large Pharma potential Growth driver: • Add Large Pharma • Execute strategy on Large Pharma Biosecure Act • Build Footprint in EU • Biosecure ACT becomes law in the Unites states • Introduce ADCs, mAbs, and Biologics platforms • Federal agencies must not enter in co
Slide 54: Drug Discovery Services: Expansion at current and new sites
Drug Discovery Services: Expansion at current and new sites to enable revenue growth Expansion at current sites, Greater Noida & Bengaluru Expansion at new site, Devanahalli, Bengaluru Capacity : 1,000 FTE’s ( FY25 ) → 2,000 FTE’s ( FY28 ) → 4,000 FTE’s ( FY30 ) Increasing capacity in a phased manne
Slide 55: Drug Discovery Services: Added capability in Biologics through Pierre Fabre partnership
Drug Discovery Services: Added capability in Biologics through strategic partnership with Pierre Fabre • Expanded TAM by USD 1.4 Bn. in mAbs and ADCs • Added strategic footprint in the EU • Enhanced domain expertise in ADC • Unique & cost-effective delivery model Integration complete; Investing in B
Slide 56: API Financials: Q2'FY27 & H1'FY27
API Financials : Q2’FY27 & H1’FY27 Particulars ( Rs. Cr.) Q2’FY26 Q1’FY27 Q2’FY27 Y-o-Y H1'FY26 H1'FY27 Y-o-Y • Revenue grew marginally YoY. Industry wide pricing pressure continues. Focus to increase revenue mix from Custom manufacturing Revenue 137 135 140 2% 279 276 (1%) • EBITDA margins lower Yo
Slide 57: API Vision 2030: Double revenues and increase profitability
API Vision 2030 : Double revenues and increase profitability Revenue growth is challenging due to pricing pressure. Custom manufacturing to Revenue: increase utilization 2x of FY24 Temporary challenge on margins. Shall revert on track EBITDA Margin: More than 15% Revenue: Rs. 561 Cr. Revenue: Rs. 56
Slide 58: API: Grow CDMO and custom manufacturing in API
API Grow CDMO and custom manufacturing in API Growth driver: • Grow CDMO API • Further Strengthen CDMO: Leverage GMP manufacturing capabilities for Innovative New Chemical Entities • Custom Manufacturing: Partner with large pharma to manufacture products requiring life cycle management • China plus
Slide 59: Generics
Generics
Slide 60: Global Generics market expected to grow by ~5% to 6%
Global Generics market expected to grow by ~ 5% to 6% Generics Market Growth Drivers and Trends USD Bn ~ 532 Developed Market 19 • US market to grow at 2% ~ 406 15 203 • Non-US market to grow by 5 - 7% 149 India Market 310 242 • India market to grow ~ 8-9% • Brand building and in-clinic effectivenes
Slide 61: We are building a growing, profitable & agile business model
We are building a growing, profitable & agile business model Non-US international market • Broad therapeutic coverage - CVS, CNS, GI and multi specialty • Projected to reach 2 key markets with triple digit revenue in INR Cr., Build total of 3 - 4 markets (B2B2C) • Global presence in 50+ markets - US
Slide 62: Generics Financials: Q2'FY27 & H1'FY27
Generics Financials : Q2’FY27 & H1’FY27 Particulars ( Rs. Cr.) Q2’FY26 Q1’FY27 Q2’FY27 Y-o-Y H1'FY26 H1'FY27 Y-o-Y • Revenue grew strongly YoY. Launched 2 new products in FY27. Revenue 167 173 274 64% 333 448 34% • EBITDA margins lower YoY due to change in product mix. Trailing 12-month margin at ~
Slide 63: Generics Vision 2030: Reach top quartile profitability
Generics Vision 2030: Reach top quartile profitability for similar size companies Growth momentum has started Revenue : Margin improvement on track ~2x of FY24 EBITDA Margin : 15% to 17% Revenue : Rs. 888 Cr. EBITDA Margin : 9% Revenue : Rs. 774 Cr. EBITDA Margin : 11% Revenue : Rs. 685 Cr. Revenue
Slide 64: Generics Growth Drivers
Generics Growth Drivers Launch Grow the profitable Build branded 6 to 8 new products annually Non-US international market business • Relaunch dormant ANDAs from • Launch 6 to 8 new products • Build presence in Diabetes, Roorkee and CMO network every year Dyslipidemia and Hypertension • Secure ANDAs
Slide 65: Proprietary Novel Drugs
Proprietary Novel Drugs
Slide 66: Proprietary Novel Drugs
Proprietary Novel Drugs • Develop precision oral medicines with enhanced safety and therapeutic efficacy • Focused on specific set of patients, not responding to other therapies • Low-cost in-house discovery engine to generate drug candidates, validated through partnerships • Guided by leading oncol
Slide 67: JBI-802 to address unmet medical needs in difficult to treat cancers
JBI-802 to address unmet medical needs in difficult to treat cancers • Company sponsored Phase I/II trial underway Blood Cancer • Highly differentiated for safety and efficacy than peers ET/MPN • Total Addressable Market in US ~ USD 5 Bn. • Investigator led trial initiated Lung Cancer JBI-802 NSCLC
Slide 68: Presented first clinical data for JBI-802 at SOHO 2026
Presented first clinical data for JBI-802 at SOHO 2026 • Essential Thrombocythemia (ET) is a WHO-defined myeloproliferative neoplasm (blood cancer) characterized by elevated platelets, with risks of thrombosis e.g., stroke, bleeding (hemorrhage) and progression to myelofibrosis or Leukemia, represen
Slide 69: JBI-778 to address unmet medical needs in difficult to treat cancers
JBI-778 to address unmet medical needs in difficult to treat cancers Lung Cancer • Total Addressable Market in US: USD 2.0 Bn. NSCLC with EGFR mutation Brain Tumor • High unmet need with no effective treatment option JBI-778 HGG • Total Addressable Market in US: USD 1.7 Bn. Phase I trial underway He
Slide 70: Proprietary Novel Drugs Financials: Q2'FY27 & H1'FY27
Proprietary Novel Drugs Financials : Q2’FY27 & H1’FY27 Particulars ( Rs. Cr.) Q2’FY26 Q1’FY27 Q2’FY27 Y-o-Y H1'FY26 H1'FY27 Y-o-Y • Continue to invest in a calibrated manner in two lead programs Revenue 0 0 0 0 0 EBITDA (3) (8) (10) (261%) (9) (18) (97%) 70
Slide 71: Proprietary Novel Drugs to explore monetization
Proprietary Novel Drugs to explore monetization • First clinical data from JBI-802 presented at SOHO annual meeting 2026 • Explore monetization through licensing or external fund raising 71
Slide 72: Consolidated Reported Financials – Q2'FY27 & H1'FY27
Consolidated Reported Financials – Q2’FY27 & H1’FY27 Solid revenue growth (YoY) across all business segments Particulars ( Rs. Cr. ) Q2’FY26 Q1’FY27 Q2’FY27 Y-o-Y H1'FY26 H1'FY27 Y-o-Y • Revenue grew YoY on the back of strong performance across all business segments, with CDMO Sterile Injectables de
Slide 73: Key Ratios
Key Ratios Net Debt / Ebitda to remain range bound Particulars ( Rs. Cr. ) Mar 31, 2026 Sep 30, 2026 • Net debt / Ebitda to remain range bound Net Debt ( On constant currency, Net of DIC ) 1,952 2,637 • Key ongoing Capex Projects Include Net Debt / Equity 0.28 0.32 New (6) PET Manufacturing Faciliti
Slide 74: Capital Allocation Priorities
Capital Allocation Priorities FY27-28: BUILD FY29-30: STRENGTHEN Complete & Ramp up capacity Accelerate growth & Deleverage • Leverage the completed capex to accelerate growth • Complete committed capex projects ( > ROCE threshold ) • Expand margins through operating leverage • Prioritise Quality &
Slide 75: Summary – Q2'FY27
Summary – Q2’FY27 Radio Pharmaceuticals : Ruby-Fill® maintaining growth momentum. Expect SPECT products supply to improve in H2’FY27 1 Radio Pharmacies : Competitive intensity continue in SPECT, Large PET product distribution contract for new pharmacies 2 Allergy Immunotherapy : Revenue grew YoY; EB
Slide 76: Financial Results Table
Financial Results Table Total Income ( Rs. Cr. ) Q2’FY26 Q1’FY27 Q2’FY27 growth YoY H1'FY26 H1'FY27 growth YoY Revenue (A) 1,966 2,229 2,370 21% 3,867 4,599 19% a. Radiopharma 897 1,022 1,009 13% 1,766 2,031 15% Radiopharmaceuticals 291 322 342 18% 561 664 18% Radiopharmacies 607 700 667 10% 1,204 1
Slide 77: Sustainability
Sustainability Category I ERP ESG Score 72 % Leader Recognized – Leading ESG entity EcoVadis Score 61 % DJSI Score 57% ESG Score 63% All Indian manufacturing plants are 20% reduction in Specific Water FY25 Zero Liquid Discharge Consumption v/s FY 26 target Sustainability FY25 Sustainability Report p
Slide 78: Vision 2030
Vision 2030 Revenue Reach 2x from FY24 to FY30 EBITDA Margin 23% to 25% by FY30 Net Debt Zero by FY30 RoCE High Teens by FY30 78
Slide 79: Annexure
Annexure Arvind Chokhany Group CFO, Whole-time Director
Slide 80: Executive Leadership Team
Executive Leadership Team Shyam S Bhartia Hari S Bhartia Priyavrat Bhartia Arjun S Bhartia Chairman Co-Chairman Managing Director Joint Managing Director Shantanu Jha Ashish Mukkirwar Group CHRO & Acting CEO, CFO Jubilant Biosys 80
Slide 81: Executive Leadership Team
Executive Leadership Team Harsher Singh Chris Preti CEO - Jubilant Radiopharma CEO - CDMO Sterile Injectables Dr Jaidev Rajpal Kyle Ferguson Daniel J. O’Connor CEO - Jubilant Generics CEO - Allergy Immunotherapy CEO – Jubilant Therapeutics 81
Slide 82: Shareholding Pattern
Shareholding Pattern As on 30th Sep 2026 0.6% 23.4% Promoter and Promoter Group Domestic Institutions 47.7% Foreign Institutions Non - Institutions 15.4% Employee Benefit Trust 13.0% 82
Slide 83: Glossary
Glossary Abbreviation Details Abbreviation Details CVS Cardiovascular System MEA Middle East Africa CNS Central Nervous System LATAM Latin America CDMO Contract Development Manufacturing Organization LOE Loss of exclusivity CRDMO Contract Research & Development Manufacturing Organization FDA (US) U.
Slide 84: Thanks!
Thanks!